Group 1: Overall Market Performance - As of January 5, 2026, over 280 Hong Kong-listed companies have released annual performance forecasts for the fiscal year ending December 31, 2025, with more than 10 companies providing specific earnings outlooks [1] - The precious metals prices have been rising, leading to generally positive performance in the non-ferrous metals industry, while innovative pharmaceutical companies have also seen significant growth due to increased demand in biopharmaceutical research [1] Group 2: Non-Ferrous Metals Industry - The non-ferrous metals industry is expected to be a major contributor to profits in the Hong Kong market for 2025, benefiting from rising global commodity prices and optimized production capacity [2] - Zijin Mining Group forecasts a net profit of 51 billion to 52 billion yuan for 2025, representing a year-on-year increase of approximately 59% to 62%, with a non-recurring net profit of 47.5 billion to 48.5 billion yuan, up about 50% to 53% [2] - Zijin Mining anticipates production of approximately 90 tons of gold, 1.09 million tons of copper, and 437 tons of silver in 2025, with significant increases in sales prices for these minerals [2] Group 3: Other Non-Ferrous Metals Companies - Zijin Gold International expects a net profit of approximately 1.5 billion to 1.6 billion USD for 2025, an increase of about 212% to 233% compared to the previous year, driven by increased gold production and favorable market conditions [3] - Chifeng Jilong Gold Mining anticipates a net profit of 3 billion to 3.2 billion yuan for 2025, reflecting a year-on-year increase of approximately 70% to 81%, attributed to higher gold production and sales prices [3] Group 4: Innovative Pharmaceuticals and Smart Driving - Innovative pharmaceutical company Baiaosaitu expects a net profit of 135 million yuan for 2025, a year-on-year increase of 303.57%, driven by successful overseas market expansion and growing domestic biopharmaceutical research demand [4][5] - Hesai Technology projects revenue of 3 billion to 3.5 billion yuan for 2025, with GAAP profits of 200 million to 350 million yuan, and Non-GAAP profits expected to rise to 350 million to 500 million yuan, alongside a significant increase in lidar shipments [5] Group 5: Traditional Industries Facing Challenges - Citic Resources anticipates a net profit of approximately 170 million to 230 million HKD for 2025, representing a decline of 60% to 70% year-on-year, primarily due to a significant drop in average selling prices of crude oil and rising raw material costs [6] - New Iron Ore Resources expects a net loss of approximately 2.2 million USD for 2025, attributed to decreased iron ore supply from major suppliers and weakened demand [7]

Core Viewpoint - The Hong Kong stock market is experiencing a peak in earnings forecasts for the fiscal year ending December 31, 2025, with significant growth expected in the non-ferrous metals and innovative pharmaceutical sectors due to rising commodity prices and increased demand for biopharmaceutical research [1][2]. Non-Ferrous Metals Industry - The non-ferrous metals industry is projected to be a major contributor to profits in the Hong Kong stock market for 2025, benefiting from rising global commodity prices and optimized production capacity [4]. - Zijin Mining Group expects a net profit of approximately 51 billion to 52 billion yuan for 2025, representing a year-on-year increase of about 59% to 62% [4]. - The increase in Zijin Mining's profits is attributed to higher production volumes and sales prices of gold, copper, and silver [5]. - Zijin Gold International anticipates a net profit of about 1.5 billion to 1.6 billion USD for 2025, an increase of approximately 212% to 233% compared to the previous year, driven by increased gold production and favorable market conditions [6]. - Chifeng Jilong Gold Mining expects a net profit of 3 billion to 3.2 billion yuan for 2025, reflecting a year-on-year increase of about 70% to 81%, primarily due to higher gold production and sales prices [6]. Innovative Pharmaceuticals and Smart Driving - The innovative pharmaceutical sector is also expected to see significant profit growth, with companies like Baiaosaitu forecasting a net profit of 135 million yuan for 2025, a year-on-year increase of 303.57% [9]. - The growth in Baiaosaitu's profits is attributed to successful expansion in overseas markets and the increasing demand for biopharmaceutical research in China [10]. - Hesai Technology projects revenues of 3 billion to 3.5 billion yuan for 2025, with a significant increase in lidar shipments expected to reach 1.2 million to 1.5 million units, representing a year-on-year growth of 139% to 200% [11]. Traditional Industries Facing Challenges - In contrast to the growth in non-ferrous metals and innovative sectors, some traditional industries are experiencing cyclical pressures, with companies like CITIC Resources forecasting a net profit decline of 60% to 70% for 2025 due to falling oil prices and rising raw material costs [14]. - CITIC Resources expects a net profit of approximately 170 million to 230 million HKD, significantly impacted by the decrease in average selling prices of crude oil and the loss of profits from joint ventures [14]. - New Mine Resources anticipates a net loss of approximately 2.2 million USD for 2025, primarily due to reduced iron ore supply and weak demand [14].

Group 1 - The Chinese innovative pharmaceutical industry has transitioned from "R&D accumulation" to "value validation," with significant acceleration expected by 2025, as evidenced by record-breaking figures in overseas licensing transactions and new drug approvals [1][4] - In 2025, the total amount of overseas licensing transactions for Chinese innovative drugs reached $135.655 billion, with 157 deals, significantly surpassing the previous year's figures of $51.9 billion and 94 deals, indicating strong international recognition of China's innovative drug value [5][17] - A total of 76 innovative drugs were approved for market entry in China in 2025, including 47 chemical drugs, 23 biological products, and 6 traditional Chinese medicines, marking a historic high and showcasing China's growing strength in the global biopharmaceutical innovation sector [5][17] Group 2 - The innovative drug sector performed well in the capital markets in 2025, with the Hong Kong innovative drug index rising by 66.52%, outperforming the Hang Seng Index's 27.77% increase, while the A-share CS innovative drug index rose by 19.34%, exceeding the CSI 300 Index's 17.66% [6][18] - The current market trend is characterized as a systematic re-evaluation of the value of Chinese innovative drugs, driven by three synergistic factors: improved policy efficiency, optimized capital ecology, and leading global R&D scale [10][22] - Policies have been established to support the entire lifecycle of innovative drugs, including measures for accelerated review and multi-tiered payment systems, enhancing the efficiency of drug approval processes [10][21][22] Group 3 - The capital ecosystem for innovative drugs has been optimized, with government-led funds and market-driven investments providing continuous financial support for the entire lifecycle of drug development [10][23] - As of December 31, 2024, there were 3,575 active innovative drug projects in China, leading globally, with the number of first-in-class (FIC) drug pipelines increasing from 9 to 120 between 2015 and 2024, representing over 30% of the global total [10][23]

Core Viewpoint - Beijing Hotgen Biotech Co., Ltd. has established a successful model of "Beijing R&D, Hebei Production" to leverage regional advantages and enhance its production capacity in the field of in vitro diagnostics [1][2][3]. Group 1: Company Overview - Hotgen Biotech was founded in June 2005 and is headquartered in Daxing District, Beijing [1]. - The company focuses on innovative biotechnology solutions, including early disease screening, diagnosis, and treatment [1]. Group 2: Strategic Development - The company recognized the collaborative potential of Beijing, Tianjin, and Hebei around 2014-2015 and began exploring suitable locations for large-scale production [2]. - In 2016, Hotgen decided to establish a production base in Langfang, Hebei, to utilize the advantages of regional integration [2]. - The company has built a cross-regional collaboration system with R&D in Beijing and production in Hebei, enhancing efficiency in research and manufacturing [2][3]. Group 3: Financial and Operational Highlights - Hotgen's project for an annual production capacity of 12 million in vitro diagnostic reagents and 850 supporting instruments was funded with approximately RMB 287.82 million [2][3]. - Upon full production, the project is expected to generate annual revenue of approximately RMB 214.40 million and a net profit of about RMB 44.97 million, with an investment recovery period of 8.05 years [3]. - By 2024, the company anticipates achieving approximately RMB 511 million in revenue, primarily from in vitro diagnostic product sales [3]. Group 4: Product Development and Innovation - In December 2025, Hotgen received three medical device registration certificates, marking significant advancements in women's health, nutritional monitoring, and anemia management [4]. - The company is implementing a dual-driven strategy of "diagnostics + innovative drugs," focusing on antibody and nucleic acid drugs through partnerships with innovative pharmaceutical companies [5][6]. - Hotgen has established the "X-Gen AI New Drug Discovery and Design Research Center" to enhance drug development through advanced AI technologies [7].

Domestic Macro Viewpoints - Recent policies have led to a rebound in economic expectations, with December construction PMI rising by 3.2 points to 52.8%[5] - December manufacturing PMI increased by 0.9 points to 50.1%, marking the first return to the 50% line since March of the previous year[5] - The expected economic growth rate for 2025 is around 5%, with a slight increase in the likelihood of a strong start in Q1 2026[5] Overseas Macro Viewpoints - The U.S. economy is expected to rebound due to the end of government shutdowns and a cumulative 75bps rate cut by the Federal Reserve since September 2025[5] - Anticipation of Trump's visit to China in April may enhance market risk appetite through increased diplomatic engagement[5] - The midterm elections are likely to lead to more accommodative fiscal and monetary policies, supporting U.S. stock markets throughout the year[5] Equity Market Viewpoints - A-share market is expected to experience a spring rally, driven by liquidity expectations and positive sentiment from overseas markets[5] - The AI industry chain remains a key focus, with investments in hardware, storage, and applications like robotics expected to grow[5] - Industries that have not fully launched yet, such as innovative pharmaceuticals and gaming, may also see new market opportunities[5] Bond Market Viewpoints - Interest rates are expected to slightly decline after the New Year, with 10-year rates potentially returning to around 1.80%[6] - Concerns about fiscal expansion and new regulations on public fund redemptions have eased, contributing to a more stable bond market outlook[6] Currency Market Viewpoints - The RMB has appreciated against the USD, with the onshore and offshore rates breaking the 7.0 mark due to seasonal demand and policy adjustments[9] - The RMB is expected to maintain an upward trend in January, supported by pre-Spring Festival settlement demand, but may stabilize in February[9] Quantitative Allocation Recommendations - The report suggests a positive outlook for growth-oriented ETFs in the A-share market, with specific recommendations for various sectors[10]

证券研究报告：医药生物 | 公司点评报告 发布时间：2026-01-06 股票投资评级 资料来源：聚源，中邮证券研究所 公司基本情况 | 最新收盘价（元） | 34.16 | | --- | --- | | 总股本/流通股本（亿股）10.27 | / 7.66 | | 总市值/流通市值（亿元）351 | / 262 | | 周内最高/最低价 52 | 48.80 / 24.86 | | 资产负债率(%) | 45.0% | | 市盈率 | -26.28 | | 第一大股东 | HKSCC NOMINEES | | LIMITED | | 研究所 分析师:盛丽华 SAC 登记编号:S1340525060001 Email:shenglihua@cnpsec.com 君实生物(688180) EGFR/HER3 ADC 双抗进入 II 期临床，联用方案有望 实现弯道超车 l EGFR/HER3 ADC 双抗进入 II 期临床，联用方案可期 事件：公司在 CDE 药物临床试验登记与信息公示平台网站上，登 记了一项 EGFR/HER3 双抗药物 JS212，联合 PD-1 抗体特瑞普利，或 PD-1/VEGF 双抗 ...

Group 1 - The pharmaceutical and biotechnology industry in China is expected to experience a convergence of industrial, policy, and capital cycles by 2026, leading to a performance inflection point and valuation reconstruction for innovative drugs [1] - Key areas of focus include next-generation innovative therapies represented by ADCs, bispecific/multispecific antibodies, cell and gene therapies, and small nucleic acids [1] - The medical device industry is seeing a reduction in policy impact, with domestic companies achieving technological breakthroughs in high-end sectors and rapid growth in overseas market expansion, indicating potential performance recovery for related companies [1] Group 2 - The blood products market is witnessing continuous growth in demand and plasma collection, with a clear trend of resource concentration towards leading companies [1] - The Guotai medical ETF (159377) tracks the innovative pharmaceutical index (399275), which has a daily price fluctuation limit of 20%, focusing on companies engaged in biotechnology, genetic engineering, and the development of new vaccines and drugs [1]

在全球经济面临诸多不确定性的背景下，国际主流媒体以及包括国际货币基金组织在内的国际机构对 2026年中国经济前景持积极预期，认为其增长韧性与转型动力将为世界注入宝贵的确定性。 经济增长预期积极 2026年中国经济的增长动力将从何而来？外媒的观察指向两个关键领域：内需市场的纵深发展和新质生 产力的蓬勃兴起。 欧洲《现代外交》杂志网站预测，随着中国促进形成更多由内需主导的经济发展模式，2026年中国经济 将在高科技、智能制造、绿色能源和服务消费等领域实现显著增长。 彭博社分析，在全球经济放缓的背景下，内需驱动将成为中国主要的增长引擎。 与此同时，中国的"新质生产力"成为国际观察家理解中国经济增长新动能的关键。英国天空新闻台阿拉 伯语频道认为，中国经济成就源于长期的产业规划和对高附加值产业的持续投入。 如果说政策与内需是经济的稳定器，那么创新则被外媒视为2026年中国经济最活跃的加速器。 英国《经济学人》在一篇探究中国迈向创新强国原因的文章中，特别关注了中国在自动驾驶和创新药两 个前沿领域的加速推进。文章认为，中国技术实力的增长，主要得益于产学研的深度融合以及国家顶层 设计的创新体系支持。 美国《纽约时报》则注意到 ...

Market Overview - The A-share market performed outstandingly in 2025, with major indices rising across the board, led by growth styles: CSI 300 up 17.66%, CSI 500 up 30.39%, CSI 1000 up 27.49%, ChiNext 50 up 57.45%, and Sci-Tech 50 up 35.92% [1] - The market in 2025 was primarily driven by liquidity easing and thematic rotation, with expectations that 2026 may enter an "earnings verification period" [1] - It is recommended to focus on policy-driven, profit recovery, and economic recovery directions, particularly in technology growth and high-end manufacturing sectors [1] Industry Focus ChiNext 50 Index - The ChiNext 50 Index serves as a direct financing platform for innovative and entrepreneurial companies, focusing on "three innovations (innovation, creation, creativity)" and "four new (new technologies, new industries, new business formats, new models)" [1] - The index emphasizes sectors such as information technology, new energy, financial technology, and pharmaceuticals, showcasing pure technology growth attributes [1] Key Sectors Technology and AI - The ChiNext 50 Index includes 52% of the information technology sector, with 23% weight in optical modules, which were among the best-performing technology tracks in 2025 [4] - The industry is experiencing a "volume and price rise" pattern, with significant growth in 800G optical modules and the commercialization of 1.6T optical modules, leading to revenue growth exceeding 50% for major manufacturers [4][16] - Long-term demand for AI computing power is expected to surge, with optical modules serving as the "transmission foundation" [4] New Energy Photovoltaics - The new energy photovoltaic sector saw significant gains in 2025, with policies stabilizing prices and a recovery in single crystal silicon prices by approximately 40% and lithium carbonate prices by about 60% [6][16] - The midstream industry chain is optimizing, with leading companies like CATL experiencing profit recovery after a price war [6][16] Pharmaceuticals and Biotechnology - The pharmaceutical sector performed well in 2025, driven by the explosive growth of innovative drugs [6] - The license-out transaction value for Chinese innovative drugs is expected to grow at a compound annual growth rate of 125% from 2019 to 2024, with AI applications in medical imaging and diagnostics accelerating revenue growth [6][16] ChiNext 50 ETF - The ChiNext 50 ETF (159949) tracks the ChiNext 50 Index, focusing on high-quality leading companies in five major technology sectors: new energy vehicles, biomedicine, electronics, photovoltaics, and internet finance [7] - The ETF has a robust liquidity profile, with an average daily trading volume of 1.471 billion yuan over the past year, ranking among the top ETFs on the Shenzhen Stock Exchange [7] - The latest fund size is 30.652 billion yuan, making it one of the largest funds tracking the ChiNext-related indices [7]

Core Viewpoint - The A-share market is expected to have significant potential in 2026, despite recent high volatility and a cautious sentiment among investors [1][7]. Valuation and Market Sentiment - A-shares are currently valued below historical averages, presenting a "valuation pit" advantage compared to international markets [1][7]. - The market's rational behavior reflects a correction of overly pessimistic expectations from previous years, primarily in specific growth and cyclical sectors rather than across the board [1][7]. Economic Outlook - The macroeconomic environment is likely to be friendly towards the stock market, with nominal GDP and corporate profit growth expected to rise from previous lows in 2026 [2][8]. - The central economic work conference indicates limited fiscal and monetary space in the first half of 2026, which may constrain domestic demand across various sectors, including real estate, automotive, and infrastructure [2][8]. Investment Opportunities - Three main investment themes are identified for 2026: 1. New demand driven by technological advancements [2][8]. 2. Opportunities in overseas markets [2][8]. 3. Industries with significant supply constraints [2][8]. Sector Focus - The AI sector is highlighted as a key growth area, with increased global capital expenditure driving demand for computing power, semiconductors, and industrial metals [3][9]. - The pharmaceutical sector, particularly innovative drug exports, is expected to benefit from China's engineering talent, with more products likely to enter international markets in 2026 [3][9]. Supply Constraints - The supply of non-ferrous metals is expected to remain limited, with prices likely to continue rising due to constrained exploration and geopolitical factors [4][10]. - The chemical sector may also see price stabilization or rebounds due to a lack of new production capacity in certain areas [4][10].